Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets soar higher
Tue, 29 Oct 01:30 pm

Backed by sustained buying interest, Indian share markets continued to climb higher in the post-noon trading session. All the sectoral indices are trading in the green with banking, metal and realty stocks being the biggest gainers.

BSE-Sensex is up 203 points and NSE-Nifty is trading 103 points up. BSE Mid Cap is trading up 0.9% and BSE Small Cap index is trading up 0.2%. The rupee is trading at 61.4 to the US dollar.

Majority of the FMCG stocks are trading in the green with Jyothy Consumer and Hindustan Unilever (HUL) being the biggest gainers.Gillette India and Lakshmi Energy are among the few stocks trading in the red. Dabur declared its second quarter results for FY14. The company posted a 14.8% YoY growth in revenues during the quarter on a strong volume growth of 11%. The domestic FMCG business grew by 14.4% YoY whereas international business grew by a faster 26% YoY during the quarter. Barring hair care, all the product segments in the consumer care business clocked double-digit growth. The company managed to expand operating margin by 1.7% to 18.8% aided by easing input costs and other expenses (both as a proportion of sales). Only the consumer care business reported incremental EBIT margin with the EBIT margin of the food business contracting by 2.6% YoY. Net profit grew by 23.4% YoY during the quarter. The company has declared an interim dividend of Rs 0.75 per equity share of face value Re. 1 each for FY14. Dabur's stock is currently trading up by 0.8%.

Most of the Indian pharma company stocks are trading in green with Dishman pharma and Biocon Ltd leading the pack of gainers. As per the financial daily, India's Department for Pharmaceuticals (DoP) has rejected Dr Reddy's petition against ceiling prices fixed by National Pharmaceutical Pricing Authority (NPPA. NPPA has fixed ceiling prices for various formulations that has impacted the revenues of the Indian and MNC pharma companies. However, various pharma companies have questioned regulators regarding the prices fixed on various drugs. Even Dr Reddy's had filed similar petition, where it had challenged the price fixed for omeprazole 20mg capsules under new pricing policy. However, the court rejected Dr Reddy's plea. Reportedly, there are more than 120 brands of omeprazole 20 mg available in the Indian market. The verdict is also negative for the companies who are selling the drug having omeprazole 20 mg. Various Indian pharma companies such as Cadila Healthcare, Alembic Pharmaceuticals, Cipla, Ranbaxy and others are selling this drug. Even various MNC pharma companies such as Novartis Abbott are selling these drugs. Further, Cipla and Ranbaxy have around seven brands for this formulation.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Indian share markets soar higher". Click here!

  

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

More Views on News

Most Popular

Is Intraday Trading For You? (Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks (Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution (Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE FMCG


May 14, 2021 (Close)

S&P BSE FMCG 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS